The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: Design and baseline characteristics

Controlled Clinical Trials

Volumn 24, Issue 6, 2003, Pages 752-775

  Bots, Michiel L ^a   Evans, Gregory W ^b   Riley, Ward ^b   Meijer, Rudy ^a   McBride, Karen H ^c   Paskett, Electra D ^b   Helmond, Frans A ^c   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease prevention; Carotid intima media thickness; Estrogen; Fractures; Hormone therapy; Osteoporosis; Tibolone

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EUROPE; FEMALE; FEMUR; HUMAN; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; NORMAL HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TUNICA MEDIA; ULTRASOUND; UNITED STATES;

EID: 0346221351     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(03)00096-5     Document Type: Article

References (104)

1. Rich-Edwards J.W., Manson J.E., Hennekens C.H., Buring J.E. The primary prevention of coronary heart disease in women. N Engl J Med. 332:1995;1758-1766.
2. Mosca L., Manson J.E., Sutherland S.E., et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 96:1997;2468-2482.
3. Binder E.F., Williams D.B., Schechtman K.B., Jeffe D.B., Kohrt W.M. Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial. Ann Intern Med. 134:2001;754-760.
4. Vita J.A., Keaney J.F. Jr. Hormone replacement therapy and endothelial function: the exception that proves the rule? Arterioscler Thromb Vasc Biol. 21:2001;1867-1869.
5. de Kleijn M.J., Wilmink H.W., Bots M.L., et al. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. Atherosclerosis. 159:2001;357-365.
6. Herrington D.M., Espeland M.A., Crouse J.R. III, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 21:2001;1955-1961.
7. Manolio T.A., Furberg C.D., Shemanski L., et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation. 88:1993;2163-2171.
8. Westendorp I.C., Bots M.L., Akkerhuis J.M., et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. Stroke. 30:1999;2562-2567.
9. Dubuisson J.T., Wagenknecht L.E., D'Agostino R.B. Jr., et al. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes. Diabetes Care. 21:1998;1790-1796.
10. Nabulsi A.A., Folsom A.R., Szklo M., et al. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 94:1996;1857-1863.
11. Muscat B.Y., Brincat M., Galea R. Carotid artery wall thickness in women treated with hormone replacement therapy. Maturitas. 27:1997;47-53.
12. Sator M.O., Joura E.A., Gruber D.M., et al. The effect of hormone replacement therapy on carotid arteries: measurement with a high frequency ultrasound system. Maturitas. 30:1998;63-68.
13. McGrath B.P., Liang Y.L., Teede H., et al. Age-related deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol. 18:1998;1149-1156.
14. Teede H.J., Liang Y.L., Shiel L.M., McNeil J.J., McGrath B.P. Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function. J Am Coll Cardiol. 34:1999;131-137.
15. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-63.
16. Falkeborn M., Persson I., Adami H.O., et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 99:1992;821-828.
17. Rosenberg L., Palmer J.R., Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 137:1993;54-63.
18. Mann R.D., Lis Y., Chukwujindu J., Chanter D.O. A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. J Clin Epidemiol. 47:1994;307-312.
19. Brett K.M., Madans J.H. Long-term survival after coronary heart disease. Comparisons between men and women in a national sample. Ann Epidemiol. 5:1995;25-32.
20. Newton K.M., LaCroix A.Z., McKnight B., et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol. 145:1997;269-277.
21. Heckbert S.R., Weiss N.S., Koepsell T.D., et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med. 157:1997;1330-1336.
22. Stampfer M.J., Colditz G.A., Willett W.C., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 325:1991;756-762.
23. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
24. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 87:1996;6-12.
25. Grodstein F., Stampfer M.J., Colditz G.A., et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
26. O'Keefe J.H. Jr., Kim S.C., Hall R.R., et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol. 29:1997;1-5.
27. Abu-Halawa S.A., Thompson K., Kirkeeide R.L., et al. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol. 82:1998;409-413.
28. Sullivan J.M., El Zeky F., Vander Z.R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol. 79:1997;847-850.
29. Varas-Lorenzo C., Garcia-Rodriguez L.A., Perez-Gutthann S., Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 101:2000;2572-2578.
30. Shlipak M.G., Angeja B.G., Go A.S., et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 104:2001;2300-2304.
31. Heckbert S.R., Kaplan R.C., Weiss N.S., et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med. 161:2001;1709-1713.
32. Hu F.B., Stampfer M.J., Manson J.E., et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 343:2000;530-537.
33. Posthuma W.F., Westendorp R.G., Vandenbroucke J.P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 308:1994;1268-1269.
34. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-323.
35. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
36. Herrington D., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 343:2000;522-529.
37. Adams M.R., Anthony M.S., Manning J.M., Golden D.L., Parks J.S. Low dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet Gynecol. 96:2000;250-255.
38. Williams J.K., Anthony M.S., Honore E.K. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 15:1995;827-836.
39. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;217-221.
40. Constantine G, Trott E, Pickar JH. Cardiovascular outcomes in healthy postmenopausal women taking hormone replacement therapy. Results from two large clinical trials. 4th International Symposium on Women's Health and Menopause: New strategies improved quality of life. Washington DC, May 19-23, 2001:17 (abstract).
41. Collins N, Vickers MR, on behalf of the WISDOM Trial Team. Progress on WISDOM - the women's international study of long duration oestrogen after menopause. 4th International Symposium on Women's Health and Menopause: New strategies improved quality of life. Washington DC, May 19-23, 2001: 67 (abstract).
42. de Kleijn M.J., Bots M.L., Bak A.A., et al. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas. 32:1999;195-204.
43. Angerer P., Stork S., Kothny W., Schmitt P., von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 21:2001;262-268.
44. Hodis H.N., Mack W.J., Lobo R.A., et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 135:2001;939-953.
45. Bots M.L., Hofman A., Grobbee D.E. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke. 28:1997;2442-2447.
46. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 96:1997;1432-1437.
47. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 146:1997;483-494.
48. Rohde L.E., Lee R.T., Rivero J., et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 18:1998;1765-1770.
49. Chambless L.E., Folsom A.R., Clegg L.X., et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 151:2000;478-487.
50. Yamasaki Y., Kodama M., Nishizawa H., et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care. 23:2000;1310-1315.
51. Held C., Hjemdahl P., Eriksson S.V., et al. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J. 22:2001;62-72.
52. del Sol A.I., Moons K.G., Hollander M., et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke. 32:2001;1532-1538.
53. Blankenhorn D.H., Selzer R.H., Crawford D.W., et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 88:1993;20-28.
54. Mack W.J., Selzer R.H., Hodis H.N., et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke. 24:1993;1779-1783.
55. Furberg C.D., Adams H.P. Jr., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 90:1994;1679-1687.
56. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 92:1995;1758-1764.
57. de Groot E., Jukema J.W., van Boven A.J., et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol. 76:1995;40C-46C.
58. Borhani N.O., Mercuri M., Borhani P.A., et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 276:1996;785-791.
59. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 101:1996;627-634.
60. Persson J., Israelsson B., Stavenow L., Holmstrom E., Berglund G. Progression of atherosclerosis in middle-aged men: effects of multifactorial intervention. J Intern Med. 239:1996;425-433.
61. MacMahon S., Sharpe N., Gamble G., et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 97:1998;1784-1790.
62. Salonen J.T., Nyyssonen K., Salonen R., et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med. 248:2000;377-386.
63. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 102:2000;1503-1510.
64. MacMahon S., Sharpe N., Gamble G., et al. Randomised placebo controlled trial of the angiotensin converting enzyme Ramipril in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 36:2000;438-443.
65. Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 103:2001;1721-1726.
66. Simon A., Gariepy J., Moyse D., Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 103:2001;2949-2954.
67. Tang R., Hennig M., Thomasson B., et al. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 18:2000;197-201.
68. Markwood T.T., Kent S.M., Coyle L.C., et al. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) - a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. Am Heart J. 141:2001;342-347.
69. Moore R.A. Livial: a review of clinical studies. Br J Obstet Gynaecol. 106:(Suppl 19):1999;1-21.
70. Albertazzi P., Di Micco R., Zanardi E. Tibolone: a review. Maturitas. 30:1998;295-305.
71. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 82:1997;1752-1756.
72. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 86:2001;5396-5404.
73. von Eckardstein A., Schmiddem K., Hovels A., et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 159:2001;433-439.
74. Zandberg P., Peters J.L.M., Demacker P.N., et al. Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause. 8:2001;96-105.
75. Zandberg P., Peters J.L., Demacker P.N., et al. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol. 18:1998;1844-1854.
76. Espeland M.A., Applegate W., Furberg C.D., et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 142:1995;1011-1019.
77. Espeland M.A., Byington R.P., Hire D., et al. Analysis strategies for serial multivariate ultrasonographic data that are incomplete. Stat Med. 11:1992;1041-1056.
78. Espeland M.A., Craven T.E., Riley W.A., et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke. 27:1996;480-485.
79. Bots M.L., Witteman J.C., Grobbee D.E. Carotid intima-media wall thickness in elderly women with and without atherosclerosis of the abdominal aorta. Atherosclerosis. 102:1993;99-105.
80. Bots M.L., Hofman A., Grobbee D.E. Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam Study. Arterioscler Thromb. 14:1994;1885-1891.
81. Allan P.L., Mowbray P.I., Lee A.J., Fowkes F.G. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke. 28:1997;348-353.
82. Mattace R.F., Rosato M., Talerico A., Cotronei P., Mattace R. Intimal-medial thickness of the common carotid arteries and lower limbs atherosclerosis in the elderly. Minerva Cardioangiol. 47:1999;321-327.
83. Davis P.H., Dawson J.D., Mahoney L.T., Lauer R.M. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study. Circulation. 100:1999;838-842.
84. Arad Y., Spadaro L.A., Roth M., et al. Correlations between vascular calcification and atherosclerosis: a comparative electron beam CT study of the coronary and carotid arteries. J Comput Assist Tomogr. 22:1998;207-211.
85. Vliegenthart R., Oudkerk M., Song B., et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction measures of atherosclerosis: the Rotterdam Coronary Calcification Study. Eur Heart J. 23:2002;1596-1603.
86. Geroulakos G., O'Gorman D.J., Kalodiki E., Sheridan D.J., Nicolaides A.N. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J. 15:1994;781-785.
87. Crouse J.R. III, Craven T.E., Hagaman A.P., Bond M.G. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation. 92:1995;1141-1147.
88. Adams M.R., Nakagomi A., Keech A., et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 92:1995;2127-2134.
89. Visona A., Pesavento R., Lusiani L., et al. Intimal medial thickening of common carotid artery as indicator of coronary artery disease. Angiology. 47:1996;61-66.
90. Hulthe J., Wikstrand J., Emanuelsson H., et al. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke. 28:1997;1189-1194.
91. Khoury Z., Schwartz R., Gottlieb S., et al. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. Am J Cardiol. 80:1997;1429-1433.
92. Enderle M.D., Schroeder S., Ossen R., et al. Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart. 80:1998;349-354.
93. Lekakis J.P., Papamichael C.M., Cimponeriu A.T., et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol. 85:2000;949-952.
94. Balbarini A., Buttitta F., Limbruno U., et al. Usefulness of carotid intima-media thickness measurement and peripheral B-mode ultrasound scan in the clinical screening of patients with coronary artery disease. Angiology. 51:2000;269-279.
95. Mack W.J., LaBree L., Liu C., Selzer R.H., Hodis H.N. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis. 150:2000;371-379.
96. Byington R.P., Evans G.W., Espeland M.A., et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 100:1999;e14-e17.
97. Tang R., Hennig M., Thomasson B., et al. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 18:2000;197-201.
98. Barnabei V.M., Phillips T.M., Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med. 8:1999;1167-1172.
99. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 100:1999;717-722.
100. Espeland M.A., Marcovina S.M., Miller V., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation. 97:1998;979-986.
101. Blakely J.A. The heart and estrogen/progestin replacement study revisited: hormone replacement therapy produced net harm, consistent with the observational data. Arch Intern Med. 160:2000;2897-2900.
102. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med. 135:2001;1-8.
103. Psaty B.M., Smith N.L., Lemaitre R.N., Vos H.L., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 285:2001;906-913.
104. Mendelsohn M.E., Karas R.H. The time has come to stop letting the HERS tale wag the dogma. Circulation. 104:2001;2256-2259.